Favorable Safety Results From First Subjects of ANGANY’s New Biologic Against Allergy to Cats, Clinical Study to Move Ahead

QUEBEC CITY–(BUSINESS WIRE)–ANGANY inc. announces that it has received a unanimous recommendation from its Safety Review Committee to press ahead with its First-in-Human study of ANG-101, the company’s innovative cat allergy therapeutic candidate. This clinical study is an open label, single site evaluation of the safety, allergenicity and immunogenicity of this First-in-class biologic. The study is conducted at Imperial College London. The decision to continue the study as planned was based on the excellent safety data gathered from the first three (3) enrolled patients, called “sentinels”. The latter have been administered the product without reporting any adverse event. This justifies moving ahead with the enrolment of the remainder of the total of 20 participants in the study of which 50% have already been randomized. Moreover, the preliminary skin tests results suggest that ANG-101 is significantly hypo-allergenic when compared to commercially available cat allergen extract. The clinical study is expected to be completed by the end of this year, with final report expected in early 2024. On the basis of such results, a CTA will be file for a Phase 1 study to be initiated in France in the first half of 2024.

“Thanks to the dedicated study team, this project will be completed swiftly, and final study outcomes should soon become available, allowing for the early preparation of the next clinical trial,‘’ stated Patrick Colin, Vice-president, Clinical Development at ANGANY.

‘’This first evidence of safety for our cat allergy novel class biologic, along with the successful conduct of this First-in-Human trial, constitute milestone events on which ANGANY can build its ANG-101 clinical development program with confidence,’’ mentioned Christine Guillen, CEO of ANGANY.

About ANGANY

ANGANY is a Franco-Canadian private clinical-stage biotech company pioneering a new immunotherapy approach to overcome the challenge of allergy. ANGANY’s eBioparticle™ technology makes for biologics of a new generation to be administered as vaccines. ANGANY’s eBioparticle-Potentiated Immunotherapy™ also opens-up new prospects in several fields of application beyond allergy in human and animal health, notably in cancer immunotherapy. The company operates a cGMP pilot production unit in Quebec, as well as an R&D laboratory in France.

For more information: www.angany.com.

Contacts

Investors Relations :

Guy Tropper MD FRCSC

Co-Founder and Executive Vice-President

[email protected]